Transcatheter aortic valve implantation in patients with uninterrupted vitamin K antagonists.
Pierre RobertMariama AkodadBenoit LattucaThomas GandetJean-Christophe MaciaLaurent SchmutzDelphine DelsenyChristophe PiotFlorence LeclercqGuillaume CaylaPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2022)
TAVI with uninterrupted VKA treatment seems feasible and safe with a low risk of major bleeding and vascular complications in this first single-center experience. Particular caution is advocated in high body mass index patients and to keep INR < 2.5.
Keyphrases
- transcatheter aortic valve implantation
- aortic stenosis
- ejection fraction
- aortic valve
- body mass index
- aortic valve replacement
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- transcatheter aortic valve replacement
- atrial fibrillation
- peritoneal dialysis
- prognostic factors
- heart failure
- physical activity
- direct oral anticoagulants
- catheter ablation
- weight gain
- coronary artery disease
- patient reported outcomes
- weight loss